CN108349910A - 葡萄糖摄取抑制剂 - Google Patents
葡萄糖摄取抑制剂 Download PDFInfo
- Publication number
- CN108349910A CN108349910A CN201680048825.8A CN201680048825A CN108349910A CN 108349910 A CN108349910 A CN 108349910A CN 201680048825 A CN201680048825 A CN 201680048825A CN 108349910 A CN108349910 A CN 108349910A
- Authority
- CN
- China
- Prior art keywords
- mixture
- phenyl
- amino
- alkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *(C=C1)c2c1cncn2 Chemical compound *(C=C1)c2c1cncn2 0.000 description 9
- VHBQLMWJNLFWRW-MDZDMXLPSA-N C/C(/c(cc1)ccc1Nc1nc(Cl)nc2ncccc12)=C\N Chemical compound C/C(/c(cc1)ccc1Nc1nc(Cl)nc2ncccc12)=C\N VHBQLMWJNLFWRW-MDZDMXLPSA-N 0.000 description 1
- AHGAACXGSQNSRA-UHFFFAOYSA-N CC(C(F)(F)F)NC(CCl)=[U] Chemical compound CC(C(F)(F)F)NC(CCl)=[U] AHGAACXGSQNSRA-UHFFFAOYSA-N 0.000 description 1
- RSBNUUYSIVHGLG-CYVAKJSSSA-N CC(C(N(C(C)(C)C)I)O)Oc1cc(-c2nc(COC3)c3c(Nc(cc3)ccc3/C(/C=N)=C/N)n2)ccc1 Chemical compound CC(C(N(C(C)(C)C)I)O)Oc1cc(-c2nc(COC3)c3c(Nc(cc3)ccc3/C(/C=N)=C/N)n2)ccc1 RSBNUUYSIVHGLG-CYVAKJSSSA-N 0.000 description 1
- QPGBEWARCLFEMI-UHFFFAOYSA-N CC(C)(C)CNC(COC1=CC(c2nc(CCOC3)c3c(Nc(cc3)ccc3-c3c[nH]nc3)n2)=CCC1)=O Chemical compound CC(C)(C)CNC(COC1=CC(c2nc(CCOC3)c3c(Nc(cc3)ccc3-c3c[nH]nc3)n2)=CCC1)=O QPGBEWARCLFEMI-UHFFFAOYSA-N 0.000 description 1
- YUSPRHLOCJQIJD-GQSQHTQSSA-N CC(C)C(N(CC1)Cc2c1nc(-c1cccc(OCC(NC3CCCC3)=O)c1)nc2Nc(cc1)ccc1/C(/C=N)=C/N)=O Chemical compound CC(C)C(N(CC1)Cc2c1nc(-c1cccc(OCC(NC3CCCC3)=O)c1)nc2Nc(cc1)ccc1/C(/C=N)=C/N)=O YUSPRHLOCJQIJD-GQSQHTQSSA-N 0.000 description 1
- POELCNOXXVNBIH-GTGGOXMFSA-O CC(C)NC(C(C)OC(C=CC1)=CC1c1nc(COC2)c2c(N(C)c(cc2)ccc2/C(/C=[NH2+])=C/N)n1)=O Chemical compound CC(C)NC(C(C)OC(C=CC1)=CC1c1nc(COC2)c2c(N(C)c(cc2)ccc2/C(/C=[NH2+])=C/N)n1)=O POELCNOXXVNBIH-GTGGOXMFSA-O 0.000 description 1
- MTKKAWFUOGPLIW-UHFFFAOYSA-O CC(C)NC(COc1cc(-c(nc2Nc(cc3)ccc3-c3c[nH]nc3)nc(C=[NH2+])c2NC)ccc1)=O Chemical compound CC(C)NC(COc1cc(-c(nc2Nc(cc3)ccc3-c3c[nH]nc3)nc(C=[NH2+])c2NC)ccc1)=O MTKKAWFUOGPLIW-UHFFFAOYSA-O 0.000 description 1
- OORLWRYUNTTXTF-UHFFFAOYSA-N CC(N(C1)Cc2c1c(Nc(cc1)ccc1-c1c[nH]nc1)nc(-c1cccc(OCC(NC3CCCC3)=O)c1)n2)=O Chemical compound CC(N(C1)Cc2c1c(Nc(cc1)ccc1-c1c[nH]nc1)nc(-c1cccc(OCC(NC3CCCC3)=O)c1)n2)=O OORLWRYUNTTXTF-UHFFFAOYSA-N 0.000 description 1
- IFJNZSWVCRTBHO-UHFFFAOYSA-N CC1(C)OB(c2cccc(OCC(N3CCOCC3)=O)c2)OC1(C)C Chemical compound CC1(C)OB(c2cccc(OCC(N3CCOCC3)=O)c2)OC1(C)C IFJNZSWVCRTBHO-UHFFFAOYSA-N 0.000 description 1
- JGNSWILFAVVIDD-RMDZGDJTSA-O CCC(C)(C)NC(CCOc1cc(-c2nc(CCN(CC)C3)c3c(Nc(cc3)ccc3/C(/C=[NH2+])=C/N)n2)ccc1)=O Chemical compound CCC(C)(C)NC(CCOc1cc(-c2nc(CCN(CC)C3)c3c(Nc(cc3)ccc3/C(/C=[NH2+])=C/N)n2)ccc1)=O JGNSWILFAVVIDD-RMDZGDJTSA-O 0.000 description 1
- GWXZBWDFCITNJY-LFNSWLNHSA-N CCC(C)(C)NC(COc1cc(C(C)(NC2=C3COCC2)N=C3Nc(cc2)ccc2/C(/C=N)=C/N)ccc1)=O Chemical compound CCC(C)(C)NC(COc1cc(C(C)(NC2=C3COCC2)N=C3Nc(cc2)ccc2/C(/C=N)=C/N)ccc1)=O GWXZBWDFCITNJY-LFNSWLNHSA-N 0.000 description 1
- BZFYJCMZMDGHPT-UHFFFAOYSA-N CCC(C)(C)NC(C[U]c1cc(B2OC(C)(C)C(C)(C)[O-]2)ccc1)=[O-] Chemical compound CCC(C)(C)NC(C[U]c1cc(B2OC(C)(C)C(C)(C)[O-]2)ccc1)=[O-] BZFYJCMZMDGHPT-UHFFFAOYSA-N 0.000 description 1
- OSDQJYNYKTVASJ-UHFFFAOYSA-N CCC(C)NC(COc1cc(B2OC(C)(C)C(C)(C)O2)ccc1)=O Chemical compound CCC(C)NC(COc1cc(B2OC(C)(C)C(C)(C)O2)ccc1)=O OSDQJYNYKTVASJ-UHFFFAOYSA-N 0.000 description 1
- QKSMDQXUAHSIPU-UHFFFAOYSA-N CCC(CC)NC(COC(CC(c1nc(COC2)c2c(Nc(cc2)ccc2-c2c[nH]nc2)n1)=C1)C=C1F)=O Chemical compound CCC(CC)NC(COC(CC(c1nc(COC2)c2c(Nc(cc2)ccc2-c2c[nH]nc2)n1)=C1)C=C1F)=O QKSMDQXUAHSIPU-UHFFFAOYSA-N 0.000 description 1
- VRFAXOQBGQZNJT-UHFFFAOYSA-N CCC(CC)NC(COc(cc(cc1)Br)c1F)=O Chemical compound CCC(CC)NC(COc(cc(cc1)Br)c1F)=O VRFAXOQBGQZNJT-UHFFFAOYSA-N 0.000 description 1
- WORQPKLPJSZBMM-RELWKKBWSA-N CCC/C(/c(cc1)ccc1Nc1nc(-c2cccc(OCC(NC3CCCC3)=O)c2)nc2c1[o]cc2)=C\N Chemical compound CCC/C(/c(cc1)ccc1Nc1nc(-c2cccc(OCC(NC3CCCC3)=O)c2)nc2c1[o]cc2)=C\N WORQPKLPJSZBMM-RELWKKBWSA-N 0.000 description 1
- PTLCOKYQEMUIPC-UHFFFAOYSA-N COc1cc(-c2nc(ccnc3)c3c(Cl)n2)ccc1 Chemical compound COc1cc(-c2nc(ccnc3)c3c(Cl)n2)ccc1 PTLCOKYQEMUIPC-UHFFFAOYSA-N 0.000 description 1
- IIMNKAWLLMXNFR-LFNWLSNRSA-N N/C=C(\C=N)/c(cc1)ccc1Nc1nc(-c2cccc(NC(c3cc(Cl)cnc3)=O)c2)nc2c1COC2 Chemical compound N/C=C(\C=N)/c(cc1)ccc1Nc1nc(-c2cccc(NC(c3cc(Cl)cnc3)=O)c2)nc2c1COC2 IIMNKAWLLMXNFR-LFNWLSNRSA-N 0.000 description 1
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N O=C(CCl)N1CCOCC1 Chemical compound O=C(CCl)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185223P | 2015-06-26 | 2015-06-26 | |
| US62/185223 | 2015-06-26 | ||
| PCT/US2016/039365 WO2016210330A1 (en) | 2015-06-26 | 2016-06-24 | Glucose uptake inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108349910A true CN108349910A (zh) | 2018-07-31 |
Family
ID=57586425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680048825.8A Pending CN108349910A (zh) | 2015-06-26 | 2016-06-24 | 葡萄糖摄取抑制剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10273248B2 (enExample) |
| EP (1) | EP3313825A4 (enExample) |
| JP (1) | JP2018518518A (enExample) |
| CN (1) | CN108349910A (enExample) |
| CA (1) | CA3028355A1 (enExample) |
| EA (1) | EA201890153A1 (enExample) |
| HK (1) | HK1254835A1 (enExample) |
| WO (1) | WO2016210330A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112741828A (zh) * | 2021-01-08 | 2021-05-04 | 武汉大学 | 药物联用物及其制备方法和用途 |
| WO2024046504A1 (zh) * | 2022-08-29 | 2024-03-07 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018137036A1 (en) * | 2017-01-26 | 2018-08-02 | The Royal Institution For The Advancement Of Learning / Mcgill University | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof |
| US11071735B2 (en) | 2017-04-28 | 2021-07-27 | Kadmon Corporation, Llc | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors |
| CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| ES2969536T3 (es) | 2017-06-30 | 2024-05-21 | Beijing Tide Pharmaceutical Co Ltd | Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso |
| WO2019000683A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| JP2020525525A (ja) | 2017-06-30 | 2020-08-27 | ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用 |
| CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
| WO2019126739A1 (en) | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate anti-cancer therapies |
| US10689386B2 (en) | 2018-03-07 | 2020-06-23 | Duquesne University Of The Holy Spirit | Pyrazolo[4,3-d]pyrimidines as antitumor agents |
| US12030857B2 (en) | 2018-06-25 | 2024-07-09 | Kadmon Corporation, Llc | Glucose uptake inhibitors |
| US20230084927A1 (en) * | 2019-11-13 | 2023-03-16 | Metabomed Ltd. | Glucose uptake inhibitors and uses thereof |
| US20220315598A1 (en) * | 2019-12-02 | 2022-10-06 | Shanghai Yingli Pharmaceutical Co., Ltd | Oxygen-containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof |
| EP4155308A4 (en) * | 2020-07-14 | 2024-04-17 | Wuhan LL Science and Technology Development Co., Ltd. | ROCK INHIBITOR AND PRODUCTION PROCESS AND USE THEREOF |
| CN112479913A (zh) * | 2020-11-19 | 2021-03-12 | 安徽修一制药有限公司 | 一种n,n-二乙基氯代乙酰胺的制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003059913A1 (en) * | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
| WO2012040499A2 (en) * | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
| US20120277206A1 (en) * | 2007-12-14 | 2012-11-01 | Andrea Boesciences, Inc. | Reverse transcriptase inhibitors |
| CN102791697A (zh) * | 2009-10-12 | 2012-11-21 | 瑞科西有限公司 | 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物 |
| CN103492389A (zh) * | 2011-04-21 | 2014-01-01 | 原真股份有限公司 | 用作激酶抑制剂的吡唑并[4,3-d]嘧啶 |
| WO2014055996A2 (en) * | 2012-10-05 | 2014-04-10 | Kadmon Corporation, Llc | Rho kinase inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102901456B (zh) | 2012-09-12 | 2015-10-28 | 深圳深蓝精机有限公司 | 检测装置及检测圆轴的外径、跳动值、真圆度的方法 |
| WO2016210331A1 (en) * | 2015-06-26 | 2016-12-29 | Kadmon Corporation, Llc | Treatment of infectious diseases with glucose uptake inhibitors |
-
2016
- 2016-06-24 EP EP16815426.8A patent/EP3313825A4/en not_active Withdrawn
- 2016-06-24 WO PCT/US2016/039365 patent/WO2016210330A1/en not_active Ceased
- 2016-06-24 CN CN201680048825.8A patent/CN108349910A/zh active Pending
- 2016-06-24 US US15/737,911 patent/US10273248B2/en active Active
- 2016-06-24 JP JP2017567146A patent/JP2018518518A/ja not_active Ceased
- 2016-06-24 EA EA201890153A patent/EA201890153A1/ru unknown
- 2016-06-24 CA CA3028355A patent/CA3028355A1/en not_active Abandoned
- 2016-06-24 HK HK18113929.9A patent/HK1254835A1/zh unknown
-
2019
- 2019-04-29 US US16/397,043 patent/US10988484B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003059913A1 (en) * | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
| US20120277206A1 (en) * | 2007-12-14 | 2012-11-01 | Andrea Boesciences, Inc. | Reverse transcriptase inhibitors |
| CN102791697A (zh) * | 2009-10-12 | 2012-11-21 | 瑞科西有限公司 | 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物 |
| WO2012040499A2 (en) * | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
| CN103492389A (zh) * | 2011-04-21 | 2014-01-01 | 原真股份有限公司 | 用作激酶抑制剂的吡唑并[4,3-d]嘧啶 |
| WO2014055996A2 (en) * | 2012-10-05 | 2014-04-10 | Kadmon Corporation, Llc | Rho kinase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| KATERINA MARDILOVICH ET AL.: "Targeting Rho GTPase signaling for cancer therapy", 《FUTURE ONCOLOGY》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112741828A (zh) * | 2021-01-08 | 2021-05-04 | 武汉大学 | 药物联用物及其制备方法和用途 |
| CN112741828B (zh) * | 2021-01-08 | 2022-04-26 | 武汉大学 | 药物联用物及其制备方法和用途 |
| WO2024046504A1 (zh) * | 2022-08-29 | 2024-03-07 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| US10988484B2 (en) | 2021-04-27 |
| US20180298029A1 (en) | 2018-10-18 |
| US10273248B2 (en) | 2019-04-30 |
| US20190315772A1 (en) | 2019-10-17 |
| CA3028355A1 (en) | 2016-12-29 |
| WO2016210330A1 (en) | 2016-12-29 |
| JP2018518518A (ja) | 2018-07-12 |
| EP3313825A4 (en) | 2019-03-13 |
| EA201890153A1 (ru) | 2018-06-29 |
| HK1254835A1 (zh) | 2019-07-26 |
| EP3313825A1 (en) | 2018-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10988484B2 (en) | Glucose uptake inhibitors | |
| CN103998042B (zh) | Pi3k的活性或功能的抑制剂的应用 | |
| TWI591067B (zh) | 吡唑并吡啶及吡唑并嘧啶 | |
| CN103097384B (zh) | 取代的咪唑并[1,2‑a]嘧啶和吡啶 | |
| US9580432B2 (en) | Fused pyrimidine compound or salt thereof | |
| KR20240101561A (ko) | Kras의 저해제로서의 퀴놀린 화합물 | |
| CN114026067A (zh) | 用于治疗冠状病毒和小核糖核酸病毒感染的肽模拟物 | |
| WO2019037678A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
| EP3560924A1 (de) | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren | |
| TW201639576A (zh) | 吡唑並［１，５-ａ］嘧啶類之醫藥組成物與用途 | |
| WO2017071516A1 (zh) | 一种蛋白激酶抑制剂及其制备方法和医药用途 | |
| WO2015158310A1 (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
| TW201625619A (zh) | 抑制瞬態電位受器ａ１離子通道 | |
| US10729691B2 (en) | Treatment of infectious diseases with glucose uptake inhibitors | |
| WO2023246903A1 (zh) | 含硒杂环类化合物及其药用组合物和应用 | |
| WO2022253283A1 (zh) | 一类蛋白激酶降解剂及其用途 | |
| WO2024032661A1 (zh) | Kif18a抑制剂及其用途 | |
| JP6529983B2 (ja) | マラリアの予防又は治療に有用なトリアミノピリミジン化合物 | |
| EP4229063A1 (en) | Novel inhibitors of pikfyve and methods using same | |
| US20240366598A1 (en) | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof | |
| WO2015058661A1 (zh) | Bcr-abl激酶抑制剂及其应用 | |
| KR20230035036A (ko) | 이중 키나제-브로모도메인 억제제 | |
| CN116789673B (zh) | 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用 | |
| CN115151257B (zh) | 用于治疗与dux4表达相关的疾病的新颖化合物 | |
| TW202334132A (zh) | Ｓａｒｍ１酶活性抑制劑及其應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180731 |
|
| WD01 | Invention patent application deemed withdrawn after publication |